Pov

AI will not fix biopharma economics by improving discovery alone

The larger productivity problem spans development, evidence, regulatory execution and the capital consumed before a medicine reaches patients.

Related macro

Pharmaceuticals, biotechnology and life sciences

Turn scientific innovation into durable portfolio value as patent exposure, access pressure and R&D economics reshape life sciences.

Discover the macro

Editorial overview

Articles

Focus

Strategic challenges

POV

Strategic impact

What we observe

Get in touch

Get in touch with our experts to discuss your priorities, explore potential opportunities, and understand how our capabilities can support your organization.

Contact us
The content on this website is provided for general information only and does not constitute financial, legal, tax, or professional advice. KeynesMoore makes no representations regarding the accuracy or completeness of the information provided. Users are solely responsible for any decisions made based on this material. For comprehensive analysis and tailored strategic guidance, please schedule a consultation with our expert team. All content is proprietary to KeynesMoore and protected by copyright. Any unauthorized reproduction, distribution, or use is strictly prohibited.
®2026 KeynesMoore. All Rights Reserved.